ArticleHypertension (Dallas, Tex. : 1979)2018
Bradykinin Stimulates Renal Na
Open access · bronzeAbstract read
In one paragraph
Article in Hypertension (Dallas, Tex. : 1979), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Modifying Dietary Sodium and Potassium Intake: An End to the 'Salt Wars'?Hypertension (Dallas, Tex. : 1979) · 2024Review
- Inwardly rectifying KAmerican journal of physiology. Cell physiology · 2022Review
- EAST/SeSAME Syndrome and Beyond: The Spectrum of Kir4.1- and Kir5.1-Associated Channelopathies.Frontiers in physiology · 2022Review
- Targeting Plasma Kallikrein With a Novel Bicyclic Peptide Inhibitor (THR-149) Reduces Retinal Thickening in a Diabetic Rat Model.Investigative ophthalmology & visual science · 2021Article
- Looking for pathways related to COVID-19: confirmation of pathogenic mechanisms by SARS-CoV-2-host interactome.Cell death & disease · 2021Article
- Inwardly rectifying potassium channel 5.1: Structure, function, and possible roles in diseases.Genes & diseases · 2021Review
- COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies.Molecular biology reports · 2021Review
- Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector.Advanced therapeutics · 2021Review
- The Implications of Zinc Therapy in Combating the COVID-19 Global Pandemic.Journal of inflammation research · 2021Review
- Indomethacin: Can It Counteract Bradykinin Effects in COVID-19 Patients?Current pharmacology reports · 2021Review
- Angiotensin-Converting Enzyme 2 in the Pathogenesis of Renal Abnormalities Observed in COVID-19 Patients.Frontiers in physiology · 2021Review
- A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm.eLife · 2020Article
- Diurnal Regulation of Renal Electrolyte Excretion: The Role of Paracrine Factors.Annual review of physiology · 2020Review
- Inhibition of AT2R and Bradykinin Type II Receptor (BK2R) Compromises High KHypertension (Dallas, Tex. : 1979) · 2020Article
- Dietary Potassium Downregulates Angiotensin-I Converting Enzyme, Renin, and Angiotensin Converting Enzyme 2.Frontiers in pharmacology · 2020Article
- Intracellular chloride: a regulator of transepithelial transport in the distal nephron.Current opinion in nephrology and hypertension · 2019Review
- Kir4.1/Kir5.1 in the DCT plays a role in the regulation of renal KAmerican journal of physiology. Renal physiology · 2019Article
- Imbalance in Renal Vasoactive Enzymes Induced by Mild Hypoxia: Angiotensin-Converting Enzyme Increases While Neutral Endopeptidase Decreases.Frontiers in physiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Dan-Dan ZhangFrom the Department of Physiology, Harbin Medical University, China (D.-D.Z., Y.X., H.Z., X.-W.G., X.-X.M., L.G., J.-L.W., X.-P.D., R.G.).
Zhong-Xiuzi GaoDepartment of Pharmacology, New York Medical College, Valhalla (Z.-X.G., P.W., D.-H.L., W.-H.W.).
Carlos P VioDepartment of Physiology, Center for Aging and Regeneration Care-UC, Pontificia Universidad Catolica de Chile, Santiago (C.P.V.).
Yu XiaoFrom the Department of Physiology, Harbin Medical University, China (D.-D.Z., Y.X., H.Z., X.-W.G., X.-X.M., L.G., J.-L.W., X.-P.D., R.G.).
Peng WuDepartment of Pharmacology, New York Medical College, Valhalla (Z.-X.G., P.W., D.-H.L., W.-H.W.).
Hao ZhangFrom the Department of Physiology, Harbin Medical University, China (D.-D.Z., Y.X., H.Z., X.-W.G., X.-X.M., L.G., J.-L.W., X.-P.D., R.G.).
Xi-Wen GuoFrom the Department of Physiology, Harbin Medical University, China (D.-D.Z., Y.X., H.Z., X.-W.G., X.-X.M., L.G., J.-L.W., X.-P.D., R.G.).
Xin-Xin MengFrom the Department of Physiology, Harbin Medical University, China (D.-D.Z., Y.X., H.Z., X.-W.G., X.-X.M., L.G., J.-L.W., X.-P.D., R.G.).
Li GuFrom the Department of Physiology, Harbin Medical University, China (D.-D.Z., Y.X., H.Z., X.-W.G., X.-X.M., L.G., J.-L.W., X.-P.D., R.G.).
Jun-Lin WangFrom the Department of Physiology, Harbin Medical University, China (D.-D.Z., Y.X., H.Z., X.-W.G., X.-X.M., L.G., J.-L.W., X.-P.D., R.G.).
Xin-Peng DuanFrom the Department of Physiology, Harbin Medical University, China (D.-D.Z., Y.X., H.Z., X.-W.G., X.-X.M., L.G., J.-L.W., X.-P.D., R.G.).
Dao-Hong LinDepartment of Pharmacology, New York Medical College, Valhalla (Z.-X.G., P.W., D.-H.L., W.-H.W.).
Wen-Hui WangDepartment of Pharmacology, New York Medical College, Valhalla (Z.-X.G., P.W., D.-H.L., W.-H.W.).
Ruimin GuFrom the Department of Physiology, Harbin Medical University, China (D.-D.Z., Y.X., H.Z., X.-W.G., X.-X.M., L.G., J.-L.W., X.-P.D., R.G.) ruimingu2916@163.com wenhui_wang@nymc.edu.
Harbin Medical University · CNNew York Medical College · US
Funding
Role of Kir4.1 in Regulating NCC and ROMK in DCTR01DK054983 · NIDDK · NEW YORK MEDICAL COLLEGE · PI ELLISON, DAVID H, WANG, WENHUI · 2001 to 2020
$7.4MKir5.1 regulates Kir4.1 ubiquitination by Nedd4-2 in DCTR01DK115366 · NIDDK · NEW YORK MEDICAL COLLEGE · PI LIN, DAO-HONG · 2018 to 2021
$1.5MRole of Kir4.1 in Regulating NCC and ROMK in DCTR56DK054983 · NIDDK · NEW YORK MEDICAL COLLEGE · PI ELLISON, DAVID H, WANG, WENHUI · 2021 to 2021
$100kNIDDK NIH HHS R01 DK054983NIDDK NIH HHS R01 DK115366NIDDK NIH HHS R56 DK054983
Abstract
Stimulation of BK2R (bradykinin [BK] B2 receptor) has been shown to increase renal Na
Indexed as
AnimalsBradykininFemaleImmunohistochemistryIon TransportKidney Tubules, DistalMaleMembrane PotentialsMiceMice, Inbred C57BLMice, KnockoutModels, AnimalNatriuresisPatch-Clamp TechniquesPotassium Channels, Inwardly RectifyingSodiumBradykininPotassium Channels, Inwardly RectifyingSodiumSolute Carrier Family 12, Member 3bradykinin B2, receptordiureticshypertensionion transportsodium-chloride symporter
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.